v3.26.1
Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total Stockholder's Equity
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Treasury Stock
Deferred Compensation
Noncontrolling Interests
Total
Beginning Balance at Oct. 31, 2024 $ 656,922 $ 2 $ 2,300,031 $ (1,641,550) $ (1,561) $ (1,198) $ 1,198 $ 10,687 $ 667,609
Beginning Balance at (in shares) at Oct. 31, 2024   20,375,932              
Sale of common stock, net of fees 5,892   5,892           5,892
Sale of common stock, net of fees (in shares)   690,711              
Common stock issued, non-employee compensation 82   82           82
Common stock issued, non-employee compensation (in shares)   8,335              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (468)   (468)           (468)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   75,834              
Share based compensation 2,142   2,142           2,142
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation (232)       (232)       (232)
Adjustment for deferred compensation           (70) 70    
Adjustment for deferred compensation (in shares)   (7,040)              
Contributions received for the sale of noncontrolling interest               4,000 4,000
Distribution to noncontrolling interest               (600) (600)
Net Loss (28,326)     (28,326)       (4,060) (32,386)
Ending Balance at Jan. 31, 2025 635,212 $ 2 2,306,879 (1,669,876) (1,793) (1,268) 1,268 10,027 645,239
Ending Balance at (in shares) at Jan. 31, 2025   21,143,772              
Beginning Balance at Oct. 31, 2024 656,922 $ 2 2,300,031 (1,641,550) (1,561) (1,198) 1,198 10,687 667,609
Beginning Balance at (in shares) at Oct. 31, 2024   20,375,932              
Effect of foreign currency translation                 54
Net Loss                 (70,135)
Ending Balance at Apr. 30, 2025 609,177 $ 2 2,318,607 (1,707,925) (1,507) (1,314) 1,314 9,762 618,939
Ending Balance at (in shares) at Apr. 30, 2025   22,776,193              
Beginning Balance at Jan. 31, 2025 635,212 $ 2 2,306,879 (1,669,876) (1,793) (1,268) 1,268 10,027 645,239
Beginning Balance at (in shares) at Jan. 31, 2025   21,143,772              
Sale of common stock, net of fees 7,665   7,665           7,665
Sale of common stock, net of fees (in shares)   1,626,319              
Common stock issued, non-employee compensation 46   46           46
Common stock issued, non-employee compensation (in shares)   12,013              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (7)   (7)           (7)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   6,102              
Share based compensation 4,824   4,824           4,824
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation 286       286       286
Adjustment for deferred compensation           (46) 46    
Adjustment for deferred compensation (in shares)   (12,013)              
Distribution to noncontrolling interest               (565) (565)
Net Loss (38,049)     (38,049)       300 (37,749)
Ending Balance at Apr. 30, 2025 609,177 $ 2 2,318,607 (1,707,925) (1,507) (1,314) 1,314 9,762 618,939
Ending Balance at (in shares) at Apr. 30, 2025   22,776,193              
Beginning Balance at Oct. 31, 2025 662,179 $ 5 2,493,318 (1,829,449) (1,695) (1,406) 1,406 9,105 $ 671,284
Beginning Balance at (in shares) at Oct. 31, 2025   46,075,237             46,075,237
Sale of common stock, net of fees 54,917   54,917           $ 54,917
Sale of common stock, net of fees (in shares)   6,377,246              
Common stock issued, non-employee compensation 46   46           46
Common stock issued, non-employee compensation (in shares)   6,209              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (584)   (584)           (584)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   156,759              
Share based compensation 2,042   2,042           2,042
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation (74)       (74)       (74)
Adjustment for deferred compensation           (47) 47    
Adjustment for deferred compensation (in shares)   (6,209)              
Contributions received for the sale of noncontrolling interest               4,000 4,000
Distribution to noncontrolling interest               (637) (637)
Net Loss (22,860)     (22,860)       (3,191) (26,051)
Ending Balance at Jan. 31, 2026 694,866 $ 5 2,548,939 (1,852,309) (1,769) (1,453) 1,453 9,277 704,143
Ending Balance at (in shares) at Jan. 31, 2026   52,609,242              
Beginning Balance at Oct. 31, 2025 662,179 $ 5 2,493,318 (1,829,449) (1,695) (1,406) 1,406 9,105 $ 671,284
Beginning Balance at (in shares) at Oct. 31, 2025   46,075,237             46,075,237
Effect of foreign currency translation                 $ (115)
Net Loss                 (103,680)
Ending Balance at Apr. 30, 2026 719,430 $ 6 2,651,450 (1,930,216) (1,810) (1,502) 1,502 9,082 $ 728,512
Ending Balance at (in shares) at Apr. 30, 2026   63,549,362             63,549,362
Beginning Balance at Jan. 31, 2026 694,866 $ 5 2,548,939 (1,852,309) (1,769) (1,453) 1,453 9,277 $ 704,143
Beginning Balance at (in shares) at Jan. 31, 2026   52,609,242              
Sale of common stock, net of fees 100,392 $ 1 100,391           100,392
Sale of common stock, net of fees (in shares)   10,861,233              
Common stock issued, non-employee compensation 49   49           49
Common stock issued, non-employee compensation (in shares)   6,558              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (107)   (107)           (107)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   78,887              
Share based compensation 2,018   2,018           2,018
Reclassification of stock-based compensation liability to equity 960   960           960
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation (41)       (41)       (41)
Adjustment for deferred compensation           (49) 49    
Adjustment for deferred compensation (in shares)   (6,558)              
Distribution to noncontrolling interest               (473) (473)
Net Loss (77,907)     (77,907)       278 (77,629)
Ending Balance at Apr. 30, 2026 $ 719,430 $ 6 $ 2,651,450 $ (1,930,216) $ (1,810) $ (1,502) $ 1,502 $ 9,082 $ 728,512
Ending Balance at (in shares) at Apr. 30, 2026   63,549,362             63,549,362